Peanut vs Other Food Oral Immunotherapy: Trends from an Outpatient Allergy Clinic in Boise, ID

被引：0
|
作者：
Monje, Kahlil [1 ]
Sadegh, Mojtaba [2 ]
Talreja, Neetu [1 ]
机构：
[1] Allergy Grp, Boise, ID USA
[2] Boise State Univ, Boise, ID USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
378
引用
收藏
页码：AB122 / AB122
页数：1
相关论文
共 41 条
  • [41] The safety and tolerability of AR101, an oral immunotherapy (OIT) pharmaceutical formulation for peanut allergy, after more than 1 year of treatment: results from an ongoing phase 2b clinical trial (ARC002), including low-dose (300 mg/day) and high-dose (2000 mg/day) maintenance regimens
    Rachid, R. A.
    Bird, J. A.
    Spergel, J. M.
    Jones, S. M.
    Assa'ad, A. H.
    Vickery, B.
    Wang, J.
    Leonard, S. A.
    Laubach, S. S.
    Kim, E. H.
    Davis, B. P.
    Welch, M. J.
    Heimall, J.
    Cianferoni, A.
    MacGinnitie, A. J.
    Crestani, E.
    Bennett, S.
    Elfont, R. M.
    Burks, A. W.
    ALLERGY, 2016, 71 : 105 - 105
12345